BioNTech to Present Oncology Data at ESMO 2024

TL;DR

BioNTech dropping new oncology trial data at ESMO Sept 27-30.

AI Summary

On September 5, 2024, BioNTech SE announced its intention to present clinical trial data for several oncology pipeline assets. The presentations will occur at the European Society for Medical Oncology (ESMO) Congress 2024, taking place from September 27-30, 2024, in Spain. This event is a significant platform for showcasing advancements in cancer research and treatment.

Why It Matters

The presentation of clinical trial data at a major oncology congress like ESMO is crucial for BioNTech to demonstrate the progress and potential of its drug candidates to the scientific community and investors.

Risk Assessment

Risk Level: low — This filing is an announcement of upcoming data presentation, not a financial event or material change in business operations.

Key Players & Entities

• BioNTech SE (company) — Registrant
• European Society for Medical Oncology (ESMO) Congress 2024 (company) — Event where data will be presented
• September 5, 2024 (date) — Date of announcement
• September 27-30, 2024 (date) — Dates of ESMO Congress

FAQ

From the Filing

0001776985-24-000079.txt : 20240905 0001776985-24-000079.hdr.sgml : 20240905 20240905085358 ACCESSION NUMBER: 0001776985-24-000079 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240905 FILED AS OF DATE: 20240905 DATE AS OF CHANGE: 20240905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 241280044 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kesmo20245sep2024.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On September 5, 2024, BioNTech SE announced that it will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (ESMO) Congress 2024 in Barcelona, Spain from September 13-17, 2024. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: September 5, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024 EX-99.1 2 a99_1240905xbntxprxesmo202.htm EX-99.1 Document Exhibit 99.1          BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024 MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech’s clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy approaches. “We believe that the future of cancer treatment will be driven by the combination of modalities, including immunomodulators, targeted and mRNA-based therapies,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech . “At this year’s ESMO, we will present data from three clinical trials with BNT327/PM8002, one of the key backbones for our combination treatment strategy. This bispecific antibody will